These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 29186439)
21. Efficacy and safety of adding rivaroxaban to the anti-platelet regimen in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials. Yuan J BMC Pharmacol Toxicol; 2018 May; 19(1):19. PubMed ID: 29720261 [TBL] [Abstract][Full Text] [Related]
22. [PEGASUS or COMPASS? A guide for a wise clinical choice.]. Brunetti ND; De Gennaro L; Di Biase M; Caldarola P Recenti Prog Med; 2019 Nov; 110(11):518-520. PubMed ID: 31808430 [TBL] [Abstract][Full Text] [Related]
23. Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. Eikelboom JW; Bhatt DL; Fox KAA; Bosch J; Connolly SJ; Anand SS; Avezum A; Berkowitz SD; Branch KRH; Dagenais GR; Félix C; Guzik TJ; Hart RG; Maggioni AP; Muehlhofer E; Sharma M; Shestakovska O; Yusuf S J Am Coll Cardiol; 2021 Jul; 78(1):14-23. PubMed ID: 34210409 [TBL] [Abstract][Full Text] [Related]
24. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial. Anand SS; Caron F; Eikelboom JW; Bosch J; Dyal L; Aboyans V; Abola MT; Branch KRH; Keltai K; Bhatt DL; Verhamme P; Fox KAA; Cook-Bruns N; Lanius V; Connolly SJ; Yusuf S J Am Coll Cardiol; 2018 May; 71(20):2306-2315. PubMed ID: 29540326 [TBL] [Abstract][Full Text] [Related]
25. Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence. Weitz JI; Angiolillo DJ; Geisler T; Heitmeier S Thromb Haemost; 2020 Aug; 120(8):1147-1158. PubMed ID: 32594508 [TBL] [Abstract][Full Text] [Related]
26. Revascularisation for Symptomatic Peripheral Artery Disease: External Applicability of the VOYAGER PAD Trial. Søgaard M; Nielsen PB; Skjøth F; Larsen TB; Eldrup N Eur J Vasc Endovasc Surg; 2022 Feb; 63(2):285-294. PubMed ID: 34924303 [TBL] [Abstract][Full Text] [Related]
27. The evolving treatment of peripheral arterial disease: preventing ischaemic events in the post-COMPASS era. Kaplovitch E; Anand SS Cardiovasc Res; 2019 Oct; 115(12):e121-e124. PubMed ID: 31321405 [No Abstract] [Full Text] [Related]
28. Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. Vanassche T; Verhamme P; Anand SS; Shestakovska O; Fox KA; Bhatt DL; Avezum A; Alings M; Aboyans V; Maggioni AP; Widimsky P; Berkowitz SD; Yusuf S; Connolly SJ; Eikelboom JW; Bosch J Eur J Prev Cardiol; 2020 Feb; 27(3):296-307. PubMed ID: 31615291 [TBL] [Abstract][Full Text] [Related]
29. Optimizing the Safe Use of Direct Oral Anticoagulants in Older Patients: A Teachable Moment. Sennesael AL; Dogné JM; Spinewine A JAMA Intern Med; 2015 Oct; 175(10):1608-9. PubMed ID: 26237648 [No Abstract] [Full Text] [Related]
30. Oral factor Xa inhibitors and risk of subdural hematoma: COMPASS trial results and meta-analysis. Catanese L; Eikelboom JW; Bosch J; Shestakovska O; Ng K; Nayar S; Perera KS; Shoamanesh A; Sharma M; Hart RG Neurology; 2020 Aug; 95(5):e480-e487. PubMed ID: 32651298 [TBL] [Abstract][Full Text] [Related]
32. Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both. Fox KAA; Anand SS; Aboyans V; Cowie MR; Debus ES; Zeymer U; Monje D; Vogtländer K; Lawatscheck R; Gay A Am Heart J; 2020 Apr; 222():166-173. PubMed ID: 32092505 [TBL] [Abstract][Full Text] [Related]
33. VOYAGER PAD contributes to medical therapy for peripheral artery disease. Farber A J Vasc Surg; 2020 Dec; 72(6):1843-1844. PubMed ID: 33222822 [No Abstract] [Full Text] [Related]
34. Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. Guzik TJ; Ramasundarahettige C; Pogosova N; Lopez-Jaramillo P; Dyal L; Berkowitz SD; Muehlhofer E; Bhatt DL; Fox KAA; Yusuf S; Eikelboom JW J Am Coll Cardiol; 2021 Feb; 77(5):511-525. PubMed ID: 33538248 [TBL] [Abstract][Full Text] [Related]
35. Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System. Kataruka A; Mahtta D; Akeroyd JM; Hira RS; Kazi DS; Spertus JA; Bhatt DL; Petersen LA; Ballantyne CM; Virani SS Cardiovasc Drugs Ther; 2021 Jun; 35(3):533-538. PubMed ID: 32880803 [TBL] [Abstract][Full Text] [Related]
36. Network Meta-analysis of the Benefit of Aspirin with Rivaroxaban vs. Clopidogrel for Patients with Stable Symptomatic Lower Extremity Arterial Disease. Ambler GK; Nordanstig J; Behrendt CA; Twine CP Eur J Vasc Endovasc Surg; 2021 Oct; 62(4):654-655. PubMed ID: 34452837 [No Abstract] [Full Text] [Related]
37. Rivaroxaban 2.5 mg. No justification for using this anticoagulant after an acute coronary syndrome. Prescrire Int; 2014 Oct; 23(153):229-32. PubMed ID: 25964962 [TBL] [Abstract][Full Text] [Related]